Coagadex Market Report 2026

Coagadex Market Overview

• The Coagadex market growth in the historic period has been driven by identification of factor ix deficiency, approval of recombinant clotting factors • Market expansion is supported by growth in rare bleeding disorder diagnosis, wider home infusion adoption • Growth Driver: Rising Prevalence Of Rare Bleeding Disorders Fuels Growth In The Coagadex Market • Market Trend: Advancements In Factor X Deficiency Treatment And Market Expansion In Mexico • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Coagadex Market?

Coagadex is a brand name for a medication used in the treatment of a rare bleeding disorder called hemophilia, specifically hemophilia B. It contains the active ingredient coagulation factor IX (recombinant), which is a clotting factor that helps control bleeding. People with hemophilia B have a deficiency or absence of factor IX, which is necessary for blood clotting. Coagadex helps to replace this missing factor, preventing and controlling bleeding episodes in patients with hemophilia B. It is typically administered through intravenous (IV) injection. The main types of indications for coagadex are hereditary factor X deficiency and other coagulation disorders. Hereditary factor X deficiency is a rare genetic bleeding disorder caused by insufficient or dysfunctional factor X, a critical protein for blood clotting. It is distributed through various channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies and is used by hospitals, clinics, homecare settings, and ambulatory surgical centers.

What Is The Coagadex Market Growth Forecast?

The growth in the forecast period can be attributed to growth in rare bleeding disorder diagnosis, wider home infusion adoption, improved reimbursement coverage, emerging market access expansion, advancements in recombinant technology. Major trends in the forecast period include rising adoption of recombinant clotting factors, expansion of rare bleeding disorder treatment, shift toward home based hemophilia care, improved access to factor replacement therapy, focus on prophylactic bleeding management.

Global Coagadex Market Segmentation

1) By Indication: Hereditary Factor X Deficiency, Other Coagulation Disorders 2) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, Retail Pharmacies 3) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers

What Is The Driver Of The Coagadex Market?

The increasing prevalence of rare bleeding disorders is expected to propel the growth of the coagadex market going forward. Rare bleeding disorders are a group of uncommon conditions that impair the blood's ability to clot, leading to excessive bleeding or difficulty stopping bleeding after an injury. The increasing prevalence of rare bleeding disorders can be attributed to several factors, including improved diagnosis, increased awareness, better access to healthcare, and genetic factors. Coagadex is used to treat rare bleeding disorders such as hereditary Factor X deficiency by replacing the missing clotting factor, helping to manage bleeding episodes effectively. For instance, in December 2023, according to the report published by the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO), a UK-based organization, 2023/24 indicates the burden of bleeding disorders, with 6,835 individuals recorded with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Therefore, the increasing prevalence of rare bleeding disorders fueled the growth of the coagadex industry.

Key Players In The Global Coagadex Market

Major companies operating in the coagadex market are Bio Products Laboratory Limited

Global Coagadex Market Trends and Insights

The key trend in the coagadex market is the development of innovative products, such as medications for factor X deficiency, aimed at effectively restoring clotting function and reducing the risk of life-threatening bleeding episodes. Factor X deficiency medications are designed to replace or activate factor X, which is a crucial clotting factor, to prevent or control bleeding in individuals with this rare genetic disorder. For instance, in May 2024, Bio Products Laboratory (BPL), a UK-based pharmaceutical company, received orphan drug marketing authorization for Coagadex in Mexico. Coagadex is the first and only treatment specifically designed for hereditary factor X deficiency, a rare genetic condition that impairs blood clotting due to insufficient factor X in the bloodstream. Individuals with this condition are at risk of severe, life-threatening bleeding episodes. The approval of Coagadex is particularly significant for patients in Mexico, where there is limited epidemiological data on ultra-rare bleeding disorders and a lack of awareness among healthcare professionals regarding the disease.

What Are Latest Mergers And Acquisitions In The Coagadex Market?

In October 2025, Farma Mondo UAB, a Lithuania-based provider of pharmaceutical market access and specialty distribution services, partnered with Kedrion Biopharma to exclusively distribute Coagadex across Estonia, Latvia, and Lithuania. With this deal, Farma Mondo aims to strategically expand Kedrion’s commercial reach into the Baltic markets, enhancing patient access to this rare-disease coagulation therapy. Kedrion Biopharma is an Italy-based company that collects plasma and manufactures plasma-derived therapies, including coagulation factors (such as Coagadex), immunoglobulins, and other treatments for rare disorders.

Regional Insights

North America was the largest region in the coagadex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Coagadex Market?

The coagadex market consists of sales of factor IX concentrates, factor VIII concentrates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Coagadex Market Report 2026?

The coagadex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the coagadex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.